Febrile Neutropenia in a Patient on Palliative Chemotherapy in a Resource-Limited Setting
A 64-year-old woman with metastatic pancreatic adenocarcinoma on gemcitabine plus nab-paclitaxel presents on day 9 of cycle 2 with fever of 38.6°C, rigors, and hypotension (BP 88/54 mmHg). She lives 3 hours from the cancer center, has no caregiver at home, and her local hospital has no oncology service but does have a general ICU and can give intravenous antibiotics. Labs: ANC 0.4 × 10⁹/L, platelets 45 × 10⁹/L, creatinine 180 µmol/L, lactate 3.8 mmol/L. Blood cultures are drawn. She is alert but frightened and asks whether she can be treated near home.
1. Classify her risk and outline the immediate management priorities, including the antibiotic choice and the decision about where she should be treated.
Read the worked answer
This is high-risk febrile neutropenia: profound neutropenia (ANC <0.5), hemodynamic instability, elevated lactate, and renal impairment. MASCC scoring would be low, and outpatient management is contraindicated.
Immediate priorities (the "hour-1" bundle):
- Empiric anti-pseudomonal beta-lactam within 60 minutes - piperacillin-tazobactam or cefepime; add an aminoglycoside or escalate to a carbapenem if she is unstable or has prior resistant organisms. Do not delay antibiotics for cultures or imaging.
- Fluid resuscitation for sepsis-induced hypotension, with vasopressors if she remains hypotensive after fluids.
- G-CSF can be considered in high-risk, prolonged neutropenia but is not a substitute for antibiotics.
- Transfuse platelets if <10 × 10⁹/L or if bleeding; monitor for DIC.
- Avoid nephrotoxins, adjust antibiotic doses for her creatinine, and monitor lactate and urine output.
Regarding location: she is too unstable to transfer 3 hours by road before stabilization. The safest plan is to stabilize at the local hospital with the sepsis bundle, involve the on-call oncologist by phone, and arrange transfer to the cancer center only after she is hemodynamically stable, or keep her locally with oncology tele-guidance if transfer is unsafe. Documenting this shared decision is essential.
2. She recovers and asks about preventing this again during palliative chemotherapy. What is the evidence-based approach to secondary prophylaxis, and how do you weigh it against her goals of care?
Read the worked answer
Secondary prophylaxis with G-CSF (e.g., pegfilgrastim or daily filgrastim) is indicated when a prior cycle caused febrile neutropenia, because it reduces the incidence of recurrent FN and neutropenic complications. Alternatives include dose reduction of the myelosuppressive agent or a treatment delay, which may be preferable in a palliative setting where quality of life and avoiding hospitalization matter more than dose intensity.
The key judgement is that in metastatic pancreatic cancer, chemotherapy is palliative; there is no survival benefit to preserving full dose intensity at the cost of recurrent life-threatening sepsis. A reasonable plan is to continue gemcitabine/nab-paclitaxel at a reduced dose with G-CSF support, or to simplify to single-agent gemcitabine if she values fewer hospital visits. Her distance from care and lack of a caregiver should push the plan toward lower toxicity and a written fever action plan with a thermometer, instructions to present to the nearest emergency department within 1 hour of fever, and a letter for local clinicians. Goals-of-care discussion should document her preferences about ICU admission and resuscitation.